MedPath

扬州市三药制药有限公司

Ownership
-
Established
2000-12-28
Employees
-
Market Cap
-
Website
http://www.yzdszy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

79

NMPA:79

Drug Approvals

Rifaximin

Product Name
利福昔明
Approval Number
国药准字H20070299
Approval Date
Apr 22, 2022
NMPA

Salbutamol Sulfate Inhalation Aerosol

Product Name
硫酸沙丁胺醇吸入气雾剂
Approval Number
国药准字H20123384
Approval Date
Mar 8, 2022
NMPA

Rifaximin For Suspension

Product Name
利福昔明干混悬剂
Approval Number
国药准字H20070309
Approval Date
Mar 8, 2022
NMPA

Metformin Hydrochloride and Glibenclamide Tablets(I)

Product Name
二甲双胍格列本脲片(Ⅰ)
Approval Number
国药准字H20070125
Approval Date
Sep 9, 2021
NMPA

Tramadol Hydrochloride Effervescent Granules

Product Name
盐酸曲马多泡腾颗粒
Approval Number
国药准字H20070128
Approval Date
Sep 9, 2021
NMPA

Methoxyphenamine Hydrochloride

Product Name
盐酸甲氧那明
Approval Number
国药准字H32026142
Approval Date
Mar 16, 2021
NMPA

Clarithromycin Capsules

Product Name
克拉霉素胶囊
Approval Number
国药准字H20000563
Approval Date
Jul 29, 2020
NMPA

蛇胆川贝胶囊

Approval Number
国药准字Z32020895
Approval Date
Jul 29, 2020
NMPA

Aminophylline Bromhexine and Chlorphenamine Tablets

Product Name
茶新那敏片
Approval Number
国药准字H32025464
Approval Date
Jul 29, 2020
NMPA

Furazolidone Tablets

Product Name
呋喃唑酮片
Approval Number
国药准字H32021586
Approval Date
Jul 29, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.